

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/898,234	07/03/2001	Rudolf Hauptmann	98,385-1	5009
20306 7	7590 10/04/2004		EXAMINER	
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP			O HARA, EILEEN B	
300 S. WACKI 32ND FLOOR			ART UNIT	PAPER NUMBER
CHICAGO, II			1646	
			DATE MAILED: 10/04/200	

DATE MAILED: 10/04/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>	- <u>; • </u>						
		Application No	Applican	it(s)			
		09/898,234	HAUPTM	HAUPTMANN ET AL.			
	Office Action Summary	Examiner	Art Unit				
		Eileen O'Hara	1646				
Period fo	The MAILING DATE of this commun	ication appears on the cov	er sheet with the correspond	dence address			
A SH THE - Exte after - If the - If NO - Failu Any	IORTENED STATUTORY PERIOD F MAILING DATE OF THIS COMMUNI ensions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this comm e period for reply specified above is less than thirty (3 operiod for reply is specified above, the maximum starre to reply within the set or extended period for reply reply received by the Office later than three months a led patent term adjustment. See 37 CFR 1.704(b).	CATION. of 37 CFR 1.136(a). In no event, hor nunication. 0) days, a reply within the statutory m atutory period will apply and will expir will, by statute, cause the application	wever, may a reply be timely filed inimum of thirty (30) days will be consi e SIX (6) MONTHS from the mailing da to become ABANDONED (35 U.S.C.	idered timely. ate of this communication. § 133).			
		d 00 lulu 2004					
·	Responsive to communication(s) file		nal				
2a) <u> </u>		2b)⊠ This action is non-fill for allowance except for fo		as to the merits is			
الـا(د	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
	·	oo anaon 2x parto quayro,	1000 0.5. 11, 100 0.0.2				
Disposit	ion of Claims						
5)□ 6)⊠ 7)□	Claim(s) 1,23,41,42,45-48 and 50-62 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. Claim(s) is/are allowed. Claim(s) 1,23,41,42,45-48 and 50-62 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or election requirement.						
Applicat	ion Papers						
10)	The specification is objected to by the The drawing(s) filed on is/are: Applicant may not request that any object Replacement drawing sheet(s) including	a) accepted or b) ol ction to the drawing(s) be hel the correction is required if t	d in abeyance. See 37 CFR 1 he drawing(s) is objected to. S	l.85(a). See 37 CFR 1.121(d).			
11)[_]	The oath or declaration is objected to	by the Examiner. Note th	e attached Office Action or	form PTO-152.			
Priority	under 35 U.S.C. § 119						
a)	Acknowledgment is made of a claim All b) Some * c) None of: 1. Certified copies of the priority 2. Certified copies of the priority 3. Copies of the certified copies application from the Internation	documents have been red documents have been red of the priority documents had nal Bureau (PCT Rule 17.	eived. eived in Application No nave been received in this N 2(a)).				
Attachmer	nt(s)						
	ce of References Cited (PTO-892)	4)	Interview Summary (PTO-413)				
3) 🔲 Infor	ce of Draftsperson's Patent Drawing Review (Pmation Disclosure Statement(s) (PTO-1449 or er No(s)/Mail Date		Paper No(s)/Mail Date Notice of Informal Patent Applic Other:	ation (PTO-152)			

Application/Control Number: 09/898,234

Art Unit: 1646

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application. This application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid. Applicant's submission filed on July 9, 2004 has been entered.

Claims Status

2. Claims 1, 23, 41, 42, 45-48 and 50-62 are pending in the instant application. Claims 1, 23, 45, 50, 51 and 54 have been amended and claims 2-22, 24-40, 43-44 and 49 have been canceled as requested by Applicant in the Paper filed July 9, 2004.

Withdrawn Objections and Rejections

3. Any objection or rejection of record which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.

Double Patenting

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The

Application/Control Number: 09/898,234

Art Unit: 1646

filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 1, 23, 41, 45-48 and 54-62 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1, 23, 41, 45-48 and 50-59 of copending Application No. 09/898,429. This is a <u>provisional</u> double patenting rejection since the conflicting claims have not in fact been patented. The claims are considered to be identical in scope because the only difference between the claims is the recitation in 09/898,429 that the polypeptide is not associated with human urinary proteins, but since the polypeptide is recombinantly produced, it would not be associated with urinary proteins, and this limitation therefore has no meaning and is not given weight.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4.2 Claims 42 and 51-53 remain provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 42 of U.S. Patent Application No. 09/898,429 for reasons of record in the previous office action, Paper No. 17, at pages 2-3.

Application/Control Number: 09/898,234

Art Unit: 1646

4.3 Claims 1, 23, 41, 42, 45-48 and 50-62 remain rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-44 of U.S. Patent No. 6,417,158 for reasons of record in the previous office action, Paper No. 17, at pages 2-3.

On page 5 of the response, Applicants acknowledge the rejections under the judicially created doctrine of obviousness-type double patenting and elect to address these grounds of rejection by submitting a Terminal Disclaimer or by argument upon notification that all other conditions for patentability have been met and the claims are otherwise in condition for allowance.

All other rejections have been withdrawn in response to Applicants' amendment, so with the exception of these rejections, the claims are otherwise allowable.

It is believed that all pertinent arguments have been answered.

Conclusion

5. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eileen B. O'Hara, whose telephone number is (571) 272-0878.

The examiner can normally be reached on Monday through Friday from 10:00 AM to 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached at (571) 272-0961.

Art Unit: 1646

The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal/pair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Eileen B. O'Hara, Ph.D.

Patent Examiner

EILEEN B. O'HARA PATENT EXAMINER